China Pharma Holdings Quick Ratio (CHPI) starting from the second quarter 2012 to second quarter 2011, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
China Pharma Holdings, Inc.  (CHPI)

China Pharma Holdings's Quick Ratio

CHPI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than China Pharma Holdings's Cash & cash equivalent, this led to improvement in China Pharma Holdings's Quick Ratio to 4.48 a new company high.

Within Major Pharmaceutical Preparations industry 166 other companies have achieved higher Quick Ratio than China Pharma Holdings in second quarter 2012. While Quick Ratio total ranking has improved so far during the Q2 2012 to 683, from total ranking in the first quarter 2012 at 3098.

Explain Quick Ratio?
How much Cash & cash equivalents CHPI´s has?
What are CHPI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CHPI Quick Ratio (Jun 30 2012)
Q2		 (Mar 31 2012)
Q1		 (Dec 31 2011)
Q4		 (Sep 30 2011)
Q3		 (Jun 30 2011)
Q2
Y / Y Current Liabilities Change -26.23 % 60.6 % - - -
Y / Y Cash & cash equivalent Change 174.07 % 1347.61 % - - -
Quick Ratio MRQ 4.48 2.3 2.24 2.02 1.2
CHPI's Total Ranking # 683 # 3098 # 3145 # 0 #
Seq. Current Liabilities Change -62.61 % 208.65 % -35.85 % -0.36 % -18.59 %
Seq. Cash & cash equivalent Change -27.21 % 216.25 % -28.74 % 67.07 % 284.45 %



Quick Ratio second quarter 2012 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 167
Healthcare Sector # 254
Overall Market # 683


Quick Ratio Statistics
High Average Low
4.48 2.08 0.26
(Jun 30 2012)   (Dec 31 2010)




Financial Statements
China Pharma Holdings's Current Liabilities $ 1 Millions Visit CHPI's Balance sheet
China Pharma Holdings's Cash & cash equivalent $ 4 Millions Visit CHPI's Balance sheet
Source of CHPI's Sales Visit CHPI's Sales by Geography


Cumulative China Pharma Holdings's Quick Ratio

CHPI's Quick Ratio for the trailling 12 Months

CHPI Quick Ratio

 (Jun 30 2012)
12 Months		 (Mar 31 2012)
12 Months		 (Dec 31 2011)
12 Months		 (Sep 30 2011)
12 Months		 (Jun 30 2011)
12 Months
Y / Y Current Liabilities TTM Growth 95.03 % 275.16 % - - -
Y / Y Cash & cash equivalent TTM Growth 643.38 % 2832.1 % - - -
Quick Ratio TTM 2.6 1.99 1.28 1.09 0.68
Total Ranking TTM # 4317 # 593 # 1256 # 0 #
Seq. Current Liabilities TTM Growth -5.69 % 19.27 % 19.82 % 44.71 % 81.41 %
Seq. Cash & cash equivalent TTM Growth 22.82 % 85.05 % 40.62 % 132.59 % 384.45 %

Quick ratio ranking by company, industry and sector >> Back to CHPI Financial Strength Comparisons >> Go to Compare CHPI Quick Ratio to its Competitors

On the trailing twelve months basis CHPI Cash & cash equivalent more than doubled by 174.07 % in Q2 2012 year on year, while Current Liabilities dropped to $1 millions, this led to increase in in China Pharma Holdings's Quick Ratio to 2.6, above CHPI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 299 other companies have achieved higher Quick Ratio than China Pharma Holdings. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2012 from 593 to 4317.

Explain Quick Ratio?
How much Cash & cash equivalents CHPI´s has?
What are CHPI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 300
Healthcare Sector # 633
Within the Market # 4317


trailing twelve months Quick Ratio Statistics
High Average Low
2.05 2.05 2.05
(Jun 30 2012)  




Companies with similar Quick Ratio in the quarter ending Jun 30 2012, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2012 MRQ Cash & cash equivalentJun 30 2012 MRQ Current Liabilities
Melinta Therapeutics, Inc.  12.14 $ 57.847  Millions$ 4.765  Millions
Verastem Inc   12.04 $ 38.688  Millions$ 3.213  Millions
Lixte Biotechnology Holdings Inc   12.01 $ 2.183  Millions$ 0.182  Millions
Gyre Therapeutics Inc   11.97 $ 156.478  Millions$ 13.075  Millions
Chemocentryx Inc.  11.47 $ 131.577  Millions$ 11.474  Millions
Innoviva Inc   11.46 $ 295.489  Millions$ 25.776  Millions
Novelos Therapeutics, Inc.  11.33 $ 7.201  Millions$ 0.636  Millions
Progenics Pharmaceuticals Inc  11.12 $ 47.820  Millions$ 4.302  Millions
Provectus Biopharmaceuticals Inc   11.11 $ 4.072  Millions$ 0.366  Millions
Catalyst Pharmaceuticals Inc   11.10 $ 7.515  Millions$ 0.677  Millions
Cerevel Therapeutics Holdings Inc   11.02 $ 67.720  Millions$ 6.145  Millions
Humanigen Inc  10.80 $ 27.506  Millions$ 2.546  Millions
Lexicon Pharmaceuticals Inc   10.74 $ 231.513  Millions$ 21.555  Millions
Dara Biosciences, Inc.  10.54 $ 9.346  Millions$ 0.887  Millions
Immunogen inc   9.92 $ 161.257  Millions$ 16.254  Millions
Geron Corporation  9.92 $ 118.967  Millions$ 11.992  Millions
Cumberland Pharmaceuticals Inc   9.89 $ 70.519  Millions$ 7.132  Millions
Fortress Biotech Inc   9.78 $ 38.207  Millions$ 3.907  Millions
Opus Genetics Inc   9.63 $ 8.583  Millions$ 0.891  Millions
Imunon Inc   9.60 $ 49.093  Millions$ 5.114  Millions
Tg Therapeutics Inc   8.67 $ 20.367  Millions$ 2.349  Millions
Assembly Biosciences Inc   8.50 $ 28.844  Millions$ 3.392  Millions
Biospecifics Technologies Corp  8.04 $ 8.788  Millions$ 1.094  Millions
Nanoviricides inc   8.02 $ 14.275  Millions$ 1.780  Millions
Oncternal Therapeutics Inc   7.77 $ 55.929  Millions$ 7.194  Millions
Filana Therapeutics Inc   7.56 $ 93.942  Millions$ 12.421  Millions
Aveo Pharmaceuticals Inc   7.41 $ 215.894  Millions$ 29.131  Millions
Galectin Therapeutics Inc   7.38 $ 13.130  Millions$ 1.780  Millions
Oncotelic Therapeutics Inc   7.02 $ 6.922  Millions$ 0.986  Millions
Royalty Pharma Plc  6.90 $ 9.939  Millions$ 1.440  Millions

Date modified: 2026-09-02T20:25:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.